Drugs for Multiple Endocrine Neoplasia, Type I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 127)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ethanol |
Approved |
Phase 4 |
|
64-17-5 |
702 |
Synonyms:
(C6-C9)Alkyl alcohol
[CH2Me(OH)]
[OEtH]
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
1-Hydroxyethane
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
absolute alcohol
Absolute alcohol
Absolute Alcohol
Absolute ethanol
Absolute Ethanol
Absolute ethyl alcohol
AC1L19TW
AC1Q31MM
Aethanol
Aethanol [German]
Aethylalkohol
AHD 2000
AI3-01706
Alcare hand degermer
Alcare Hand Degermer
alcohol
Alcohol
Alcohol (ethyl)
Alcohol (USP)
Alcohol [USP]
ALCOHOL 5% IN D5-W
Alcohol anhydrous
Alcohol Anhydrous
Alcohol dehydrated
Alcohol denatured
alcohol etilico
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Absolute
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, Dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, Diluted
Alcohol, ethyl
Alcohol, grain
Alcohol, Grain
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool ethylique
Alcool Ethylique
Alcool éthylique
Alcool etilico
Alcool Etilico
Algrain
Alkohol
Alkohol [German]
Alkoholu etylowego
Alkoholu Etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
bmse000297
C00469
C2H5OH
C2H6O
Caswell No. 426
Caswell No. 430
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
|
CHEMBL545
CID702
Colamine
Cologne spirit
Cologne Spirit
Cologne spirits
D000431
D00068
DB00898
Dehydrated alcohol
Dehydrated ethanol
Dehydrated Ethanol
Denatured alcohol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Denatured Ethanol
Desinfektol el
Desinfektol EL
Diluted alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
Envision Conditioner Pdd 9020
EOH
EOX
Esumiru WK 88
ETA
etanol
Etanol
Etanolo
Etanolo [Italian]
ethanol
éthanol
Ethanol (9CI)
Ethanol [JAN]
Ethanol 200 proof
Ethanol 200 Proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol Vapor
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl alc
ethyl alcohol
Ethyl alcohol
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl Alcohol Anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl Hydrate
Ethyl hydroxide
Ethyl Hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
EtOH
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
grain alcohol
Grain alcohol
Hinetoless
HSDB 531
HSDB 82
Hydroxyethane
HYDROXYETHYL GROUP
I14-12648
IMS 99
Infinity pure
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated spirit
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
MolPort-001-785-844
NCGC00091458-01
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
potato Alcohol
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spirits OF wine
spiritus vini
Spiritus vini
Spirt
SY Fresh M
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
UNII-3K9958V90M
USAF EK-1597
WLN: Q2
|
|
2 |
|
Lansoprazole |
Approved, Investigational |
Phase 4 |
|
103577-45-3 |
3883 |
Synonyms:
103577-45-3
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
A 65006
A-65006
AB00052388
Abbot brand OF lansoprazole
Abbot Brand of Lansoprazole
ABT-006
AC1L1GX8
AG 1749
AG-1749
Agopton
Almirall brand OF lansoprazole
Almirall Brand of Lansoprazole
Amarin
Aprazol
Bamalite
BIDD:GT0006
Bio-0824
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
BPBio1_001194
BRD-A49172652-001-05-7
BRN 4333393
BSPBio_001084
BSPBio_001830
C058687
C16H14F3N3O2S
CAS-103577-45-3
CG-4801
CHEBI:6375
CHEMBL480
CID3883
Compraz
CPD000058469
D00355
Dakar
DB00448
DivK1c_000920
EU-0100709
FT-0082011
HMS1571G06
HMS1922M04
HMS2052F05
HMS2093M07
HMS502N22
Hoechst brand OF lansoprazole
Hoechst Brand of Lansoprazole
Hormona brand OF lansoprazole
Hormona Brand of Lansoprazole
HSDB 7204
I06-0018
IDI1_000920
Ilsatec
KBio1_000920
KBio2_002060
KBio2_004628
KBio2_007196
KBio3_001330
KBioGR_001491
KBioSS_002060
Ketian
L 8533
L8533_SIGMA
Lancid
Lanfast
Lanproton
Lansol
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
lansoprazole
Lansoprazole
Lansoprazole (JAN/USP/INN)
Lansoprazole [Usan:Ban:Inn]
Lansoprazole [USAN:BAN:INN]
Lansoprazole abbot brand
Lansoprazole almirall brand
Lansoprazole hoechst brand
Lansoprazole hormona brand
Lansoprazole lederle brand
Lansoprazole promeco brand
Lansoprazole salvar brand
Lansoprazole sodium
lansoprazole sulphone
Lansoprazole takeda brand
Lansoprazole tap brand
Lansoprazole tecnobio brand
Lansoprazole vinas brand
Lansoprazole wyeth brand
|
Lansoprazoles
Lansoprazolum
Lansoprazolum [INN-Latin]
Lansox
Lanston
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
lanzoprazole
Lanzor
Lanzul
Lapraz
Lasoprol
Lederle brand OF lansoprazole
Lederle Brand of Lansoprazole
Limpidex
Linamarin
Lopac0_000709
Lopac-L-8533
LS-33080
Mesactol
MLS000069705
MLS-0003247.0001
MLS000759405
MLS001074170
MolPort-003-666-508
MolPort-006-394-760
Monolitum
NCGC00015615-01
NCGC00015615-02
NCGC00015615-03
NCGC00015615-06
NCGC00015615-11
NCGC00023826-03
NCGC00023826-04
NCGC00023826-05
NCGC00023826-06
NCGC00023826-07
NINDS_000920
Ogast
Ogastro
Opiren
Prestwick0_001072
Prestwick1_001072
Prestwick2_001072
Prestwick3_001072
Prevacid
Prevacid (TN)
Prevacid I.V
Prevacid I.V.
Prevacid Iv
Prevacid Solutab
Prevacid SoluTab
Prevacid, Prevacid NapraPAC, Prevacid SoluTab, Lansoprazole
PrevOnco
Prevpac
Prezal
pro Ulco
Pro Ulco
Promeco
promeco Brand OF lansoprazole
Promeco Brand of Lansoprazole
Promp
Prosogan
S1354_Selleck
Salvar brand OF lansoprazole
Salvar Brand of Lansoprazole
SAM001246544
SMR000058469
Sodium, lansoprazole
SPBio_000488
SPBio_002992
Spectrum_001580
SPECTRUM1503926
Spectrum2_000444
Spectrum3_000295
Spectrum4_000856
Spectrum5_001521
STK621169
Suprecid
TAK 390MR
TAK390MR
TAK-390MR
Takeda brand OF lansoprazole
Takeda Brand of Lansoprazole
Takepron
TAP brand OF lansoprazole
TAP Brand of Lansoprazole
tecnobio Brand OF lansoprazole
Tecnobio Brand of Lansoprazole
TL8000155
Ulpax
UNII-0K5C5T2QPG
Vinas brand OF lansoprazole
Vinas Brand of Lansoprazole
Wyeth brand OF lansoprazole
Wyeth Brand of Lansoprazole
Zoprol
Zoton
|
|
3 |
|
Dexlansoprazole |
Approved, Investigational |
Phase 4 |
|
103577-45-3, 138530-94-6 |
9578005 |
Synonyms:
138530-94-6
2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
CHEMBL1201863
CID9578005
D08903
dexlansoprazole
Dexlansoprazole
Dexlansoprazole (INN/USAN)
|
Kapidex
KS-1075
MolPort-002-885-834
T 168390
TAK 390
UNII-UYE4T5I70X
ZINC00599734
|
|
4 |
|
Doxazosin |
Approved |
Phase 4 |
|
74191-85-8 |
3157 |
Synonyms:
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
1 (4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine
1-(4-amino-6,7-Dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
74191-85-8
77883-43-3 (mesylate)
AC-11062
AC1L1FAT
AC1Q470P
AC1Q4EXN
AKOS001681453
Alfamedin
Aliud brand OF doxazosin mesylate
Almirall brand OF doxazosin mesylate
Alpharma brand OF doxazosin mesylate
Alter brand OF doxazosin mesylate
apo Doxazosin
apo-Doxazosin
Apogepha brand OF doxazosin mesylate
Apotex brand OF doxazosin mesylate
AstraZeneca brand OF doxazosin mesylate
Azupharma brand OF doxazosin mesylate
Betapharm brand OF doxazosin mesylate
BPBio1_000963
BRD-A13188892-066-03-3
BSPBio_000875
C06970
C23H25N5O5
Cantabria brand OF doxazosin mesylate
Cardular
Cardura
Cardura XL (TN)
Cardura-1
Cardura-2
Cardura-4
Carduran
Carduran neo
CHEBI:4708
CHEMBL707
ChemDiv2_005017
Ciclum brand OF doxazosin mesylate
CID3157
Cinfa brand OF doxazosin mesylate
combino Brand OF doxazosin mesylate
CPD000097306
CT Arzneimittel brand OF doxazosin mesylate
CT-Arzneimittel brand OF doxazosin mesylate
D07874
D9815_SIGMA
DB00590
Diblocin
Doxa puren
Doxacor
Doxagamma
Doxamax
Doxa-puren
Doxatensa
DoxaUro
Doxazomerck
doxazosin
Doxazosin
Doxazosin (INN)
Doxazosin [INN:BAN]
Doxazosin al
Doxazosin apogepha
Doxazosin azu
Doxazosin beta
Doxazosin findusfit
Doxazosin heumann
Doxazosin klast
Doxazosin mesilate
Doxazosin mesylate
Doxazosin monohydrochloride
Doxazosin ratiopharm
|
Doxazosin stada
Doxazosin von CT
Doxazosin wolff
Doxazosina
Doxazosina [Spanish]
Doxazosina alter
Doxazosina cinfa
Doxazosina combino pharm
Doxazosina geminis
Doxazosina normon
Doxazosina pharmagenus
Doxazosina ratiopharm
Doxazosina ur
Doxazosine
Doxazosine [French]
Doxazosin-ratiopharm
Doxazosinum
Doxazosinum [Latin]
Doxazosin-wolff
Esparma brand OF doxazosin mesylate
FindusFit brand OF doxazosin mesylate
Geminis brand OF doxazosin mesylate
Gen doxazosin
Gen-doxazosin
Genpharm brand OF doxazosin mesylate
Heumann brand OF doxazosin mesylate
Hexal brand OF doxazosin mesylate
HMS1383E01
HMS2090C20
I06-1346
IDI1_003732
Juta brand OF doxazosin mesylate
Jutalar
Kade brand OF doxazosin mesylate
L000738
Linden brand OF doxazosin mesylate
Lopac0_000474
LS-110228
Merck dura brand OF doxazosin mesylate
Mesylate, doxazosin
MolPort-001-684-491
Monohydrochloride, doxazosin
MTW Brand OF doxazosin mesylate
MTW Doxazosin
MTW-Doxazosin
NCGC00018158-06
NCGC00089775-02
neo, Carduran
Normon brand OF doxazosin mesylate
Normothen
novo Doxazosin
novo-Doxazosin
Novopharm brand OF doxazosin mesylate
Oprea1_259518
Pfizer brand OF doxazosin mesylate
Pharmagenus brand OF doxazosin mesylate
Prestwick0_000858
Prestwick1_000858
Prestwick2_000858
Prestwick3_000858
Progandol neo
Q Pharm brand OF doxazosin mesylate
Q-Pharm brand OF doxazosin mesylate
ratio Doxazosin
ratio-Doxazosin
Ratiopharm brand OF doxazosin mesylate
Ratiopharm, doxazosina
SAM002589981
Solvay brand OF doxazosin mesylate
SPBio_002796
Stadapharm brand OF doxazosin
TAD brand OF doxazosin mesylate
UK 33274
UK-33274
UNII-NW1291F1W8
Uriduct
Wolff brand OF doxazosin mesylate
Wörwag brand OF doxazosin mesylate
Zoxan
|
|
5 |
|
Phenoxybenzamine |
Approved |
Phase 4 |
|
59-96-1 |
4768 |
Synonyms:
102737-84-8
2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane
4-12-00-02204 (Beilstein Handbook Reference)
59-96-1
63-92-3 (hydrochloride)
688A
A 688
AB00053702
AC-13214
AC1L1IWT
Bensylyt
Bensylyt NEN
Bensylyte
Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine
Benzylyt
Bio2_000479
Bio2_000959
BPBio1_001000
BRN 2129697
BSPBio_000908
BSPBio_001278
BSPBio_002356
C07435
CCRIS 505
CHEBI:141434
CHEMBL753
CID4768
D08358
DB00925
Dibenylene
Dibenylin
Dibenyline
Dibenziran
Dibenzylene
Dibenzylin
Dibenzyline
Dibenzyran
DivK1c_000800
EINECS 200-446-8
Esparma brand OF phenoxybenzamine hydrochloride
Fenossibenzamina
Fenossibenzamina [DCIT]
Fenoxibenzamina
Fenoxibenzamina [INN-Spanish]
Goldshield brand OF phenoxybenzamine hydrochloride
HMS1362P19
HMS1792P19
HMS1990P19
HMS2089J09
HSDB 4005
Hydrochloride, phenoxybenzamine
IDI1_000800
IDI1_002234
|
KBio1_000800
KBio2_000618
KBio2_000858
KBio2_003186
KBio2_003426
KBio2_005754
KBio2_005994
KBio3_001095
KBio3_001096
KBioGR_000618
KBioGR_001158
KBioSS_000618
KBioSS_000858
L001197
Link brand OF phenoxybenzamine hydrochloride
Lopac0_000235
LS-43286
MolPort-001-785-595
N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine
N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine
N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine
N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine
NCGC00015121-11
NCGC00089748-03
NCGC00089748-04
NCGC00089748-05
NCGC00089748-07
NINDS_000800
N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine
NSC 37448
phenoxybenzamine
Phenoxybenzamine
Phenoxybenzamine (INN)
Phenoxybenzamine [INN:BAN]
Phenoxybenzamine Hcl
Phenoxybenzamine hydrochloride
Phenoxybenzaminum
Phenoxybenzaminum [INN-Latin]
POB
POB HCl
Prestwick0_000944
Prestwick1_000944
Prestwick2_000944
Prestwick3_000944
SPBio_001829
SPBio_003067
Spectrum_000378
Spectrum2_001815
Spectrum4_000769
Spectrum5_001370
UNII-0TTZ664R7Z
Wellspring brand OF phenoxybenzamine hydrochloride
|
|
6 |
|
Naltrexone |
Approved, Investigational, Vet_approved |
Phase 4 |
|
16590-41-3 |
5360515 |
Synonyms:
16590-41-3
16676-29-2
17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one
Antaxone
BIDD:GT0405
BPBio1_000146
BRD-K88172511-310-03-8
Bristol myers squibb brand OF naltrexone hydrochloride
Bristol-myers squibb brand OF naltrexone hydrochloride
BRN 3596648
BSPBio_000132
C07253
CCRIS 3506
Celupan
CHEBI:121459
CHEBI:7465
CHEMBL142
CID5360515
D05113
DB00704
Depade
Du pont brand OF naltrexone hydrochloride
EINECS 240-649-9
EN-1639A
HMS2089O11
HS-0002
HSDB 6750
Hydrochloride, naltrexone
Lacer brand OF naltrexone hydrochloride
lamepro Brand OF naltrexone hydrochloride
LS-92094
MLS002153483
MolPort-004-920-221
MorViva
|
Nalorex
Naltrexon
Naltrexona
Naltrexona [INN-Spanish]
naltrexone
Naltrexone
naltrexone (ReVia)
Naltrexone (USAN/INN)
Naltrexone [Usan:Ban:Inn]
Naltrexone [USAN:BAN:INN]
Naltrexone [USAN:INN:BAN]
Naltrexone Hcl
Naltrexone hydrochloride
Naltrexonum
Naltrexonum [INN-Latin]
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Nemexin
Orphan brand OF naltrexone hydrochloride
PDSP2_000847
Pharmazam brand OF naltrexone hydrochloride
Prestwick0_000116
Prestwick1_000116
Prestwick2_000116
Prestwick3_000116
PTI-555
ReVia
Schering plough brand OF naltrexone hydrochloride
Schering-plough brand OF naltrexone hydrochloride
SMP1_000206
SPBio_002071
Trexan
UM-792
UNII-5S6W795CQM
United drug brand OF naltrexone hydrochloride
Vivitrex
Vivitrol
Vivitrol (TN)
|
|
7 |
|
Parathyroid hormone |
Approved, Investigational |
Phase 4 |
|
9002-64-6 |
|
Synonyms:
Parathormone
Parathormone (human recombinant)
Parathyrin
Parathyroid hormone
Parathyroid hormone (1-84) human recombinant
Parathyroid hormone (rDNA)
|
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
8 |
|
Cinacalcet |
Approved |
Phase 4 |
|
226256-56-0 |
156419 |
Synonyms:
(R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-a-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
(R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
073, AMG
1493, KRN
226256-56-0
364782-34-3 (Hydrochloride)
AC1L4G5X
alpha-Methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphar)-hydrochloride
AMG 073
AMG073
CHEBI:48390
CID156419
Cinacalcet
Cinacalcet (USAN)
Cinacalcet [INN]
Cinacalcet hydrochloride
|
CNC
D03504
DB01012
HSDB 7318
Hydrochloride, cinacalcet
I14-3270
LS-187374
Mimpara
MolPort-003-845-954
N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
NCGC00181002-01
nchembio.2007.55-comp29
Sensipar
TL8001899
UNII-UAZ6V7728S
|
|
9 |
|
Sodium citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
10 |
|
Teriparatide |
Approved, Investigational |
Phase 4 |
|
52232-67-4 |
16133850 |
Synonyms:
52232-67-4
D06078
Forteo
Forteo (TN)
PTH (1-34)
PTH 1-34
|
Teriparatida
TERIPARATIDE
Teriparatide (genetical recombination)
Teriparatide (genetical recombination) (JAN)
Teriparatide (USAN/INN)
Teriparatide recombinant human
|
|
11 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
12 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
13 |
|
Vitamin D3 |
Approved, Nutraceutical |
Phase 4 |
|
67-97-0 |
5280795 6221 |
Synonyms:
()-Vitamin D3
(+)-vitamin D3
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
47763_SUPELCO
57651-82-8
67-97-0
7-DEHYDROCHOLESTEROL
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
ACTIVATED
Activated 7-dehydrocholesterol
Arachitol
Bio-0845
bmse000507
BPBio1_000460
BSPBio_000418
BSPBio_002408
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
Calciol
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
cholecalciferol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferols
Cholecalciferolum
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
|
CID7067440
CID7251172
CID7251174
CID9821465
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Dihydrocholesterol
DivK1c_006276
Duphafral D3 1000
Ebivit
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
FeraCol
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC375571
NSC-375571
Oleovitamin D3
Prestwick_63
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Provitamine
Provitina
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SpecPlus_000180
Spectrum_001163
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
SR-05000001559
SR-05000001559-3
ST057172
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
Vi-de-3-hydrosol
Vigorsan
VITAMIN D
Vitamin D 3
vitamin d-3
Vitamin D3
Vitamin D-3
Vitamin D3 emulsifiable
VITAMIN D3 POWDER
VITAMIN_D3
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
δ-D
|
|
14 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
15 |
|
Antacids |
|
Phase 4 |
|
|
|
16 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
17 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
18 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
19 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
21 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
22 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
23 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
24 |
|
Narcotics |
|
Phase 4 |
|
|
|
25 |
|
Narcotic Antagonists |
|
Phase 4 |
|
|
|
26 |
|
Hormones |
|
Phase 4 |
|
|
|
27 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
28 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
29 |
|
Vitamins |
|
Phase 4 |
|
|
|
30 |
|
Calciferol |
|
Phase 4 |
|
|
|
31 |
|
Nutrients |
|
Phase 4 |
|
|
|
32 |
|
Trace Elements |
|
Phase 4 |
|
|
|
33 |
|
Micronutrients |
|
Phase 4 |
|
|
|
34 |
|
Citrate |
|
Phase 4 |
|
|
|
35 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
36 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
37 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
38 |
|
Liraglutide |
Approved |
Phase 3 |
|
204656-20-2 |
44147092 |
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide (genetical recombination)
Liraglutide (rDNA origin)
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
|
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
nn 2211
NN 2211
nn2211
NN2211
NN-2211
UNII-839I73S42A
victoza
Victoza
|
|
39 |
|
Glucagon |
Approved |
Phase 3 |
|
16941-32-5 |
|
Synonyms:
Glucagon
Glucagon (recombinant dna origin)
Glucagon recombinant
Glucagon, human
|
Glucagon, porcine
Glucagone
Glucagonum
|
|
40 |
|
Somatostatin |
Approved, Investigational |
Phase 3 |
|
38916-34-6, 51110-01-1 |
53481605 |
Synonyms:
Growth hormone-inhibiting hormone (ghih)
Somatostatin
Somatostatina
Somatostatine
Somatostatinum
|
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
Synthetic growth hormone release-inhibiting hormone
Synthetic somatostatin-14
|
|
41 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
42 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
43 |
|
Incretins |
|
Phase 3 |
|
|
|
44 |
|
Insulin, Globin Zinc |
|
Phase 3 |
|
|
|
45 |
|
Glucagon-Like Peptide 1 |
|
Phase 3 |
|
|
|
46 |
|
insulin |
|
Phase 3 |
|
|
|
47 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
48 |
|
Cholestyramine Resin |
|
Phase 3 |
|
|
|
49 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
50 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 73)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors |
Completed |
NCT00204373 |
Phase 4 |
Lansoprazole (Prevacid) |
2 |
Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment |
Completed |
NCT01379898 |
Phase 4 |
Phenoxybenzamine;Doxazosin |
3 |
Randomized, Open-label Clinical Trial of Extended-Release vs. Oral Naltrexone for Alcohol Treatment in Primary Care. |
Completed |
NCT01893827 |
Phase 4 |
XR-NTX (Extended-Release Naltrexone);Oral Naltrexone (O-NTX) |
4 |
Novel Combination Therapy for Osteoporosis in Men |
Recruiting |
NCT03994172 |
Phase 4 |
Teriparatide or human parathyroid hormone (PTH) 1-34;Cinacalcet;placebo tablet |
5 |
Cinacalcet Actions in Familial Primary Hyperparathyroidism |
Completed |
NCT00325104 |
Phase 3 |
|
6 |
Liraglutide in the Treatment of Type 1 Diabetes Mellitus |
Completed |
NCT01722266 |
Phase 3 |
Liraglutide;Placebo |
7 |
Lipid Research Clinics Coronary Primary Prevention Trial (CPPT) |
Completed |
NCT00000488 |
Phase 3 |
cholestyramine |
8 |
Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study |
Not yet recruiting |
NCT02705651 |
Phase 3 |
Somatostatin-Analog |
9 |
A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention |
Unknown status |
NCT02869399 |
Phase 2 |
|
10 |
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors |
Completed |
NCT02101918 |
Phase 2 |
|
11 |
Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors |
Completed |
NCT01967537 |
Phase 2 |
68Gallium DOTATATE |
12 |
A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma |
Completed |
NCT00454363 |
Phase 2 |
Pazopanib Hydrochloride |
13 |
A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery |
Completed |
NCT02315625 |
Phase 2 |
Sunitinib;Everolimus |
14 |
A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin |
Completed |
NCT02420691 |
Phase 2 |
Ribociclib |
15 |
A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer |
Completed |
NCT00358956 |
Phase 2 |
ZD6474 (vandetanib) |
16 |
Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study |
Completed |
NCT00990535 |
Phase 2 |
Octreotide-LAR |
17 |
A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
Completed |
NCT00780663 |
Phase 2 |
Quarfloxin |
18 |
Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers |
Completed |
NCT00869050 |
Phase 2 |
Capecitabine;Temozolomide |
19 |
A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors |
Recruiting |
NCT03950609 |
Phase 2 |
Everolimus;Lenvatinib |
20 |
Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors |
Recruiting |
NCT04074135 |
Phase 2 |
68-Gallium DOTATATE |
21 |
The Perioperative Use of Dexmedetomidine and Magnesium Sulfate Compared With Traditional Anesthetic Technique for Open Resection of Pheochromocytoma. |
Recruiting |
NCT04320589 |
Phase 2 |
Dexmedetomidine;General anesthetic |
22 |
A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder |
Recruiting |
NCT03158805 |
Phase 2 |
LIRAGLUTIDE |
23 |
Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma |
Active, not recruiting |
NCT00390325 |
Phase 2 |
Sorafenib;Sorafenib Tosylate |
24 |
Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma |
Active, not recruiting |
NCT00514046 |
Phase 1, Phase 2 |
Vandetanib |
25 |
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors |
Terminated |
NCT00947167 |
Phase 2 |
pertuzumab;erlotinib |
26 |
The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial |
Completed |
NCT00001550 |
Phase 1 |
IVIg |
27 |
Phase I Trial With a Combination of Docetaxel +153 Sm-EDTMP (Samarium 153) in Patients With Hormone-Refractory Prostate Cancer |
Completed |
NCT00559429 |
Phase 1 |
Docetaxel;Docetaxel;Docetaxel;Docetaxel |
28 |
The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma |
Recruiting |
NCT02021604 |
Phase 1 |
Fluorodopa F 18 |
29 |
A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors |
Withdrawn |
NCT02831179 |
Phase 1 |
Capecitabine;Temozolomide;Veliparib |
30 |
Investigation of Prevalence and Clinical Effects of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations With DNA Sequence Analysis in Acromegaly Patients in Turkey |
Unknown status |
NCT01902420 |
|
|
31 |
A Pilot Study to Investigate Germ-Line MEN1 and SDHD Gene Mutation in Familial Cases of Carcinoid Cancer |
Unknown status |
NCT00672269 |
|
|
32 |
An Investigation of Eight Reported Cases of Small Intestinal Carcinoid Carcinoma in Multiple Family Members |
Unknown status |
NCT00662168 |
|
|
33 |
Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism |
Unknown status |
NCT01228786 |
|
|
34 |
Intra-operative Neuromodulation of the Pelvic Plexus |
Unknown status |
NCT03425240 |
|
|
35 |
A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers |
Completed |
NCT01794676 |
|
|
36 |
Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients |
Completed |
NCT01424878 |
|
|
37 |
Evaluation of the Gastrinoma in Patients With Zollinger-Ellison Syndrome |
Completed |
NCT00001254 |
|
|
38 |
Genetic Polymorphisms Associated With Histamine Disposition in Children With Vancomycin Associated Red Man Syndrome (RMS) |
Completed |
NCT00824122 |
|
|
39 |
Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients |
Completed |
NCT02465424 |
|
|
40 |
Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold |
Completed |
NCT03150758 |
|
|
41 |
Reversal of Atrial Substrate to Prevent Atrial Fibrillation - A Pilot Study |
Completed |
NCT03186976 |
|
|
42 |
The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity |
Completed |
NCT01692431 |
|
|
43 |
Longitudinal Measurement of Cortisol in Association With Mental Health and Experience of Domestic Violence and Abuse |
Completed |
NCT01632553 |
|
|
44 |
Enhancing Women's Health Through Assessing Foot Plasticity With Pregnancy |
Completed |
NCT01868074 |
|
|
45 |
Using CBPR to Reduce HIV Risk Among Immigrant Latino MSM |
Completed |
NCT03276338 |
|
|
46 |
Study and Follow-up of Multiple Endocrine Neoplasia Type 1 |
Recruiting |
NCT03348501 |
|
|
47 |
Family Studies in Metabolic Diseases and Mineral Metabolism |
Recruiting |
NCT00001345 |
|
|
48 |
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients |
Recruiting |
NCT03048266 |
|
|
49 |
Studies of Hyperparathyroidism and Related Disorders |
Recruiting |
NCT00001277 |
|
68Ga-Dotatate;18F-DOPA |
50 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
|